Abstract
Biosimilar monoclonal antibodies (mAbs) to TNF are being developed that are highly similar, but not identical to the innovator molecules. CT-P13, a biosimilar of infliximab, is the first anti-TNF mAb to get approval in South Korea, Europe and Canada. However, uncertainties remain about indication extrapolation and interchangeability.
MeSH terms
-
Antibodies, Bispecific / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use*
-
Biosimilar Pharmaceuticals / chemical synthesis
-
Colitis, Ulcerative / drug therapy*
-
Crohn Disease / drug therapy*
-
Humans
-
Infliximab / pharmacology
-
Tumor Necrosis Factor-alpha / drug effects
Substances
-
Antibodies, Bispecific
-
Antibodies, Monoclonal
-
Biosimilar Pharmaceuticals
-
CT-P13
-
Tumor Necrosis Factor-alpha
-
Infliximab